Corporate Funded Clinical Trial F&A Rate Increase
The F&A (Facilities & Administrative) rate for Corporate (industry/for profit entity) Funded Clinical Trials (CFCTs) will increase to 30% Total Direct Cost (TDC) as of January 1, 2022.
F&A cost-reimbursement rates are intended to cover institutional overhead and other expenses associated with managing and supporting sponsored projects. The University of Iowa has done a national landscape comparison to establish the new F&A rate.
The additional F&A revenue generated will be used to support a new enterprise clinical trial management system (CTMS) that will help establish standard processes for all clinical studies across the University of Iowa. Processes supported by this CTMS include study planning (with budgets), financial tracking and management, study calendars, regulatory management, and data capture, all in an environment that is compliant with 21 CFR Part 11.
The new rate will apply to all CFCTs with an effective or start date of January 1, 2022, and beyond. For corporate- and industry-sponsored clinical trials with an effective or start date prior to January 1, 2022, the current Facilities & Administrative (F&A) rate of 26% of total direct costs will apply.
For more information on F&A rates for CFCTs, please see:
Questions?
For any questions about corporate-funded clinical trial agreements, please contact DSP.
